{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T05:42:30Z","timestamp":1758346950194,"version":"3.44.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background\/Objectives<\/jats:title><jats:p>Pancreatic ductal adeno carcinoma (PDAC) in its borderline resectable (BR) stage often limits the possibility of complete resection, currently the only potential path to a cure. Neoadjuvant chemotherapy seeks to downsize tumors, thereby increasing the chances of achieving an R0 resection. However, accurately predicting resectability following such treatment remains challenging. This study aims to identify and evaluate potential biomarkers that may improve preoperative assessment of tumor resectability during exploratory laparotomy, thereby minimizing the incidence of futile surgical interventions and their associated morbidity in patients with non-resectable malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis of all patients who underwent exploratory laparotomy following neoadjuvant chemotherapy at the Department of Visceral, Thoracic, and Vascular Surgery, University Hospital Dresden, between 2011 and 2022. Employing a propensity score matching, we compared patients with resectable and unresectable pancreatic cancer. The primary endpoint was to evaluate preoperative parameters for predicting resectability status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study included initially 134 patients with neoadjuvant treated BR PDAC who underwent exploratory laparotomy. Among them, 100 (74.6%) underwent curative intended resection, and 34 (25.4%) had an explorative laparotomy only. After Propensity Score Matching we found that a pre-chemotherapy CA 19\u20139 Value &amp;lt; 450 U\/ml (OR 2.9; 95% CI: 1.04 \u2013 8.53, p = 0.04), a pre-operative CA19\u20139 value of &amp;lt; 105 U\/ml (OR 13.9; 95% CI: 3.88 \u2013 49.7, p = 0.001), and a pre - to post-chemotherapy CA19\u20139 ratio of \u2264 15% (OR 9; 95% CI: 2.48 \u2013 32.7, p = 0.001) raised the odds for resectability. Further, if the combination of a preoperative CA 19-9 &amp;lt; 105 U\/ml and a pre - to post-chemotherapy CA19\u20139 ratio of &amp;lt; 15% was present, the resectability rate increased up to 93%, compared to 30% when both parameters were above the threshold. This specific constellation was a significant predictor (OR 63; 95% CI: 7.84 \u2013 506, p = 0.001) for curative resectability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data highlight not only the significant role of the preoperative CA19\u20139 value and the pre- to post-chemotherapy CA19\u20139 ratio but, even more importantly, emphasize the critical impact of the combination of these two parameters on the resectability of BR-PDAC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1602933","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:12:48Z","timestamp":1758255168000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial"],"prefix":"10.3389","volume":"15","author":[{"given":"Florian","family":"Schepp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"von Bechtolsheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Merboth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Radulova-Mauersberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Teske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Mibelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Distler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Oehme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"doi-asserted-by":"crossref","unstructured":"Diagnosis and detection of pancreatic cancer\n          \n          \n            \n              Chu\n              LC\n            \n            \n              Goggins\n              MG\n            \n            \n              Fishman\n              EK\n            \n          \n          10.1097\/PPO.0000000000000290\n          29189329\n          Cancer J\n          23\n          2017","key":"B3","DOI":"10.1097\/PPO.0000000000000290"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326311","article-title":"Pancreatic cancer: an increasing global public health concern","volume":"71","author":"Cabasag","year":"2021","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002557","article-title":"The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma","volume":"269","author":"Ghaneh","year":"2019","journal-title":"Ann Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab133","article-title":"Technical advances in surgery for pancreatic cancer","volume":"108","author":"Schneider","year":"2021","journal-title":"Br J Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0739","article-title":"Originalarbeit Sterblichkeit und Komplikationen nach viszeralchirurgischen Operationen","volume":"116","author":"Baum","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26384","article-title":"Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma","volume":"123","author":"Brown","year":"2021","journal-title":"J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials","volume":"160","author":"van Dam","year":"2022","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09460-z","article-title":"Neoadjuvant therapy for pancreatic ductal adenocarcinoma: propensity-matched analysis of postoperative complications using ACS-NSQIP","volume":"28","author":"Krell","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/bjs\/znac354","article-title":"Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis","volume":"110","author":"Brown","year":"2023","journal-title":"Br J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.0137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.21.26931","article-title":"Imaging assessment of pancreatic cancer resectability after neoadjuvant therapy: AJR expert panel narrative review","volume":"218","author":"Soloff","year":"2022","journal-title":"Am J roentgenol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02803-y","article-title":"The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients\u2019 survival","volume":"20","author":"Jambor","year":"2022","journal-title":"World J Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1477-2574.2009.00136.x","article-title":"Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer","volume":"12","author":"McClaine","year":"2010","journal-title":"HPB"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpsurg.2024.101442","article-title":"Cost-effectiveness of staging laparoscopy with peritoneal cytology in pancreatic adenocarcinoma","volume":"61","author":"Jodidio","year":"2024","journal-title":"Curr Probl Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1055\/a-1688-0947","article-title":"S3-Leitlinie zum exokrinen Pankreaskarzinom - Langversion 2.0 - Dezember 2021 - AWMF-Registernummer: 032\/010OL","volume":"60","author":"Seufferlein","year":"2022","journal-title":"Z Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2018.07.017","article-title":"Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer","volume":"21","author":"Del Chiaro","year":"2019","journal-title":"HPB"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-020-01972-2","article-title":"Systematic review and meta-analysis of contemporary pancreas surgery with arterial resection","volume":"405","author":"Rebelo","year":"2020","journal-title":"Langenbecks Arch Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08156-3","article-title":"Serum CA19\u20139 response to neoadjuvant therapy predicts tumor size reduction and survival in pancreatic adenocarcinoma","volume":"27","author":"Al Abbas","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003049","article-title":"Importance of normalization of CA19\u20139 levels following neoadjuvant therapy in patients with localized pancreatic cancer","volume":"271","author":"Tsai","year":"2020","journal-title":"Ann Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/hpb.12154","article-title":"Serum carbohydrate antigen 19\u20139 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer","volume":"16","author":"Tzeng","year":"2014","journal-title":"HPB"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2013.10.005","article-title":"Preoperative CEA and CA 19\u20139 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - A retrospective tumor marker prognostic study","volume":"11","author":"Distler","year":"2013","journal-title":"Int J Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09584-2","article-title":"High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study","volume":"33","author":"Lee","year":"2023","journal-title":"Eur Radiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"140\u20139","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront\u00a0surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials","volume":"160","author":"van Dam","year":"2022","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-022-01833-3","article-title":"Outcomes and risks in palliative pancreatic surgery: an analysis of the German StuDoQ|Pancreas registry","volume":"22","author":"Hofmann","year":"2022","journal-title":"BMC Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017","article-title":"CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: A multicenter randomized phase III trial","volume":"35","author":"Sinn","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1602933\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:12:51Z","timestamp":1758255171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1602933\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1602933"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1602933","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"1602933"}}